Literature DB >> 25605359

Antimicrobial activity of solithromycin against serotyped macrolide-resistant Streptococcus pneumoniae isolates collected from U.S. medical centers in 2012.

D J Farrell1, R E Mendes1, R N Jones2.   

Abstract

Solithromycin, a next-generation macrolide and novel fluoroketolide, was tested against a 2012 collection of serotyped U.S. macrolide-resistant Streptococcus pneumoniae isolates associated with community-acquired bacterial pneumonia (CABP). Against all 272 isolates, solithromycin demonstrated high potency (MIC50/90, 0.06/0.25 μg/ml), and it inhibited all strains at MICs of ≤0.5 μg/ml, including the two most prevalent macrolide-resistant serotypes (19A and 35B). These data support the continued clinical development of solithromycin for the treatment of multidrug-resistant CABP.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25605359      PMCID： PMC4356815          DOI： 10.1128/AAC.04568-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates.

Authors:  Rekha Pai; Robert E Gertz; Bernard Beall
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

2.  Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States.

Authors:  David J Farrell; Keith P Klugman; Michael Pichichero
Journal:  Pediatr Infect Dis J       Date:  2007-02       Impact factor: 2.129

3.  Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine.

Authors:  Michael R Jacobs; Caryn E Good; Saralee Bajaksouzian; Anne R Windau
Journal:  Clin Infect Dis       Date:  2008-12-01       Impact factor: 9.079

4.  Sequetyping: serotyping Streptococcus pneumoniae by a single PCR sequencing strategy.

Authors:  Marcus H Leung; Kevin Bryson; Kathrin Freystatter; Bruno Pichon; Giles Edwards; Bambos M Charalambous; Stephen H Gillespie
Journal:  J Clin Microbiol       Date:  2012-05-02       Impact factor: 5.948

5.  In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.

Authors:  Pamela McGhee; Catherine Clark; Klaudia M Kosowska-Shick; Kensuke Nagai; Bonifacio Dewasse; Linda Beachel; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

6.  Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine.

Authors:  Rodrigo E Mendes; Andrew J Costello; Michael R Jacobs; Donald Biek; Ian A Critchley; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2014-05-24       Impact factor: 2.803

7.  Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates.

Authors:  David J Farrell; Helio S Sader; Mariana Castanheira; Douglas J Biedenbach; Paul R Rhomberg; Ronald N Jones
Journal:  Int J Antimicrob Agents       Date:  2010-03-07       Impact factor: 5.283

8.  Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study.

Authors:  Cynthia G Whitney; Tamar Pilishvili; Monica M Farley; William Schaffner; Allen S Craig; Ruth Lynfield; Ann-Christine Nyquist; Kenneth A Gershman; Marietta Vazquez; Nancy M Bennett; Arthur Reingold; Ann Thomas; Mary P Glode; Elizabeth R Zell; James H Jorgensen; Bernard Beall; Anne Schuchat
Journal:  Lancet       Date:  2006-10-28       Impact factor: 79.321

9.  Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011(1.).

Authors:  Sandra S Richter; Kristopher P Heilmann; Cassie L Dohrn; Fathollah Riahi; Daniel J Diekema; Gary V Doern
Journal:  Emerg Infect Dis       Date:  2013-07       Impact factor: 6.883
  9 in total
  13 in total

1.  Safety and Pharmacokinetics of Solithromycin in Subjects with Hepatic Impairment.

Authors:  Brian D Jamieson; Sabrina Ciric; Prabhavathi Fernandes
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

2.  What's old is new: Reconfiguring known antibiotics to fight drug resistance.

Authors:  Shraddha Chakradhar
Journal:  Nat Med       Date:  2016-11-08       Impact factor: 53.440

Review 3.  The macrolide antibiotic renaissance.

Authors:  George P Dinos
Journal:  Br J Pharmacol       Date:  2017-08-10       Impact factor: 8.739

4.  Efficacy of Solithromycin (CEM-101) for Experimental Otitis Media Caused by Nontypeable Haemophilus influenzae and Streptococcus pneumoniae.

Authors:  M Figueira; P Fernandes; S I Pelton
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

Review 5.  Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.

Authors:  George G Zhanel; Erika Hartel; Heather Adam; Sheryl Zelenitsky; Michael A Zhanel; Alyssa Golden; Frank Schweizer; Bala Gorityala; Philippe R S Lagacé-Wiens; Andrew J Walkty; Alfred S Gin; Daryl J Hoban; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2016-12       Impact factor: 9.546

Review 6.  Resistance to Macrolide Antibiotics in Public Health Pathogens.

Authors:  Corey Fyfe; Trudy H Grossman; Kathy Kerstein; Joyce Sutcliffe
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

7.  Ecological Effect of Solithromycin on Normal Human Oropharyngeal and Intestinal Microbiota.

Authors:  Mamun-Ur Rashid; Staffan Rosenborg; Georgios Panagiotidis; Johan Holm; Karin Söderberg Löfdal; Andrej Weintraub; Carl Erik Nord
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

8.  Population Pharmacokinetics and Safety of Solithromycin following Intravenous and Oral Administration in Infants, Children, and Adolescents.

Authors:  Daniel Gonzalez; Laura P James; Amira Al-Uzri; Miroslava Bosheva; Felice C Adler-Shohet; Susan R Mendley; John S Bradley; Claudia Espinosa; Eva Tsonkova; Kathryn Moffett; Lucila Marquez; Kari A Simonsen; Stefan Stoilov; Felix Boakye-Agyeman; Theresa Jasion; Christoph P Hornik; Robert Hernandez; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

Review 9.  A New, Potent, and Placenta-Permeable Macrolide Antibiotic, Solithromycin, for the Prevention and Treatment of Bacterial Infections in Pregnancy.

Authors:  Jeffrey A Keelan; Matthew S Payne; Matthew W Kemp; Demelza J Ireland; John P Newnham
Journal:  Front Immunol       Date:  2016-04-01       Impact factor: 7.561

10.  In Vitro Activity of Solithromycin against Bordetella pertussis, an Emerging Respiratory Pathogen.

Authors:  Dwight J Hardy; David Vicino; Prabhavathi Fernandes
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.